Structures that delineate orphanin FQ and dynorphin A pharmacological selectivities

被引:100
作者
Reinscheid, RK
Higelin, J
Henningsen, RA
Monsma, FJ
Civelli, O
机构
[1] Univ Calif Irvine, Coll Med, Dept Pharmacol, Irvine, CA 92717 USA
[2] Hoffmann La Roche Ag, CNS Res, Div Pharma, CH-4070 Basel, Switzerland
关键词
D O I
10.1074/jbc.273.3.1490
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Strict pharmacological selectivity in families of structurally related ligands and receptors may result from a key process in evolution aiming at increasing diversity in neurotransmission. An intriguing example of such exclusive specificity can be found in the newly discovered orphanin FQ (OFQ) system when it is compared with the opioid system, Both OFQ and its receptor share a high degree of sequence similarity to the opioid peptides and their corresponding receptors, respectively, However, OFQ does not activate opioid receptors, nor do the opioid peptides elicit biological activity at the OFQ receptor, We have therefore investigated the basis for the inherent selectivity of the primary structures of OFQ and dynorphin A, its closest counterpart, A series of truncated and/or chimeric peptides led to the conclusion that both peptides contain domains which establish their pharmacological selectivity, In the OFQ molecule we could delineate a domain that prevents its ability to activate the kappa-opioid receptor by apparently repelling its binding. In both peptides the selectivity-generating domains are composed of single residues in key positions together with short stretches of amino acids which do not overlap. To prove this concept, we designed a universal agonist and found it active at both the OFQ receptor and the kappa-opioid receptor, Our observations suggest that a coordinated mechanism of evolution has separated the orphanin FQ system from the opioid system.
引用
收藏
页码:1490 / 1495
页数:6
相关论文
共 16 条
[1]   Interaction of [H-3]orphanin FQ and I-125-Tyr14-orphanin FQ with the orphanin FQ receptor: Kinetics and modulation by cations and guanine nucleotides [J].
Ardati, A ;
Henningsen, RA ;
Higelin, J ;
Reinscheid, RK ;
Civelli, O ;
Monsma, FJ .
MOLECULAR PHARMACOLOGY, 1997, 51 (05) :816-824
[2]   Modes of peptide binding in G protein-coupled receptors [J].
Berthold, M ;
Bartfai, T .
NEUROCHEMICAL RESEARCH, 1997, 22 (08) :1023-1031
[3]   SPECIFIC RECEPTOR FOR THE OPIOID PEPTIDE DYNORPHIN - STRUCTURE-ACTIVITY-RELATIONSHIPS [J].
CHAVKIN, C ;
GOLDSTEIN, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1981, 78 (10) :6543-6547
[4]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[5]   RECENT DEVELOPMENTS IN THE DESIGN OF RECEPTOR SPECIFIC OPIOID-PEPTIDES [J].
HRUBY, VJ ;
GEHRIG, CA .
MEDICINAL RESEARCH REVIEWS, 1989, 9 (03) :343-401
[6]  
LAZARENO S, 1995, MOL PHARMACOL, V48, P362
[7]   Moving from the Orphanin FQ receptor to an opioid receptor using four point mutations [J].
Meng, F ;
Taylor, LP ;
Hoversten, MT ;
Ueda, Y ;
Ardati, A ;
Reinscheid, RK ;
Monsma, FJ ;
Watson, SJ ;
Civelli, O ;
Akil, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (50) :32016-32020
[8]   ISOLATION AND STRUCTURE OF THE ENDOGENOUS AGONIST OF OPIOID RECEPTOR-LIKE ORL(1) RECEPTOR [J].
MEUNIER, JC ;
MOLLEREAU, C ;
TOLL, L ;
SUAUDEAU, C ;
MOISAND, C ;
ALVINERIE, P ;
BUTOUR, JL ;
GUILLEMOT, JC ;
FERRARA, P ;
MONSARRAT, B ;
MAZARGUIL, H ;
VASSART, G ;
PARMENTIER, M ;
COSTENTIN, J .
NATURE, 1995, 377 (6549) :532-535
[9]   Orphanin FQ is a functional anti-opioid peptide [J].
Mogil, JS ;
Grisel, JE ;
Reinscheid, RK ;
Civelli, O ;
Belknap, JK ;
Grandy, DK .
NEUROSCIENCE, 1996, 75 (02) :333-337
[10]   COEVOLUTION OF LIGAND-RECEPTOR PAIRS [J].
MOYLE, WR ;
CAMPBELL, RK ;
MYERS, RV ;
BERNARD, MP ;
HAN, Y ;
WANG, XY .
NATURE, 1994, 368 (6468) :251-255